2. Sangawa H., Komeno T., Nishikawa H., Yoshida A., Takahashi K., Nomura N. et al. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob. Agents Chemother. 2013; 57(11): 5202–8.

3. Jin Z., Smith L.K., Rajwanshi V.K., Kim B., Deval J. The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5’-triphosphate towards influenza A virus polymerase. PLoS One 2013; 8(7): e68347.

4. Baranovich T., Wong S.-S., Armstrong J., Marjuki H., Webby R.J,. Webster R.G. et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J. Virol. 2013; 87(7): 3741–51.

5. Escribano-Romero E., Jiménez de Oya N., Domingo E., Saiz J.C. Extinction of West Nile Virus by Favipiravir through Lethal Mutagenesis. Antimicrob. Agents Chemother. 2017; 61(11): e01400-17. doi: 10.1128/AAC.01400-17

6. de Ávila A.I., Gallego I., Soria M.E., Gregori J., Quer J., Esteban J.I. et al. Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir. PLoS One 2016; 11(10): e0164691–e016461. https://pubmed.ncbi.nlm.nih.gov/ 27755573

7. Julander J.G., Shafer K., Smee D.F., Morrey J.D., Furuta Y. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob. Agents Chemother. 2009; 53(1): 202–9.

8. Gowen B.B., Wong M.-H., Jung K.-H., Sanders A.B., Mendenhall M., Bailey K.W. et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 2007; 51(9): 3168–76.

9. Mendenhall M., Russell A., Juelich T., Messina .EL., Smee D.F., Freiberg A.N. et al. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob. Agents Chemother. 2011; 55(2): 782–7.

10. Rocha-Pereira J., Jochmans D., Dallmeier K., Leyssen P., Nascimento M.S.J., Neyts J. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem. Biophys. Res. Commun. 2012; 424(4): 777–80.

11. Shannon A., Selisko B., Le N.-T.T., Huchting J., Touret F., Piorkowski G. et al. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat. Commun. 2020; 11(1): 4682. https://doi.org/10.1038/s41467-020-18463-z

12. Driouich J.-S, Cochin M., Lingas G., Moureau G., Touret F., Petit P.-R. et al. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nat. Commun. 2021; 12(1): 1735. https://doi.org/10.1038/s41467-021-21992-w

13. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269–71. https://doi.org/10.1038/ s41422-020-0282-0

14. Jeon S., Ko M., Lee J., Choi I., Byun S.Y., Park S. et al. Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. Antimicrob. Agents Chemother. 2020; 64(7): e00819–20. doi: 10.1128/AAC.00819-20

15. Kaptein S.J.F., Jacobs S., Langendries L., Seldeslachts L., Ter Horst S., Liesenborghs L. et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc. Nat. Acad. Sci. USA 2020; 117(43): 26955–65. doi: 10.1073/pnas.2014441117

16. Ruzhentsova T.A., Oseshnyuk R.A., Soluyanova T.N., Dmitrikova E.P., Mustafaev D.M., Pokrovskiy K.A. et al. Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19. Am. J. Transl. Res. 2021; 13(11): 12575–87. https://pubmed.ncbi.nlm.nih.gov/34956474

17. I vashchenko A.A., Dmitriev K.A., Vostokova N.V., Azarova V.N., Blinow A.A., Egorova A.N. et al. Avifavir for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin. Infect. Dis. an Off. Publ. Infect. Dis. Soc. Am. 2021; 73(3): 531–4. doi: 10.1093/cid/ciaa1176

18. Shinkai M., Tsushima K., Tanaka S., Hagiwara E., Tarumoto N., Kawada I. et al. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III. Clinical Trial. Infect. Dis. Ther. 2021; 10(4): 2489–509. doi: 10.1007/s40121-021-00517-4

19. Manabe T., Kambayashi D., Akatsu H., Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect. Dis. 2021; 21(1): 489. doi: 10.1186/s12879-021-06164-x

20. Hassanipour S., Arab-Zozani M., Amani B., Heidarzad F., Fathalipour M., Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci. Rep. 2021; 11(1): 11022. doi: 10.1038/s41598-021-90551-6

21. Finberg R.W., Ashraf M., Julg B., Ayoade F., Marathe J.G., Issa N.C. et al. US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19. Open. Forum Infect Dis. 2021; 8(12): 563. doi: 10.1093/ofid/ofab563

22. Временные методические рекомендации Минздрава России «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». М., 2021; версия 14. 233 с. https://base.garant.ru/403310712/?

[Temporary methodological recommendations of the Ministry of Health of the Russian Federation “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”]. Moscow, 2021; version 14. 233 p. (In Russ.). https://base.garant.ru/403310712/?

23. Ömeroğlu Ş.K., Temel F., Altun D., Öztop B. Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19. Turkish J. Med. Sci. 2021; 51(6): 2827–34. doi: 10.3906/sag-2101-146

24. Bosaeed M., Alharbi A., Mahmoud E., Alrehily S., Bahlaq M., Gaifer Z. et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clin. Microbiol. Infect. 2022. https://www.sciencedirect.com/science/article/pii/S1198743X2100 7345

25. https://www.appilitherapeutics.com/newsfeed/Appili-Therapeutics-Provides-Update-on-Phase-3-PRESECO-Clinical-Trial-Evaluating-Avigan%C2% AE%2FReeqonus%E2%84%A2

26. Solaymani-Dodaran M., Ghanei M., Bagheri M., Qazvini A., Vahedi E., Hassan Saadat S. et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int Immunopharmacol. 2021; 95: 107522. doi: 10.1016/j.intimp.2021.107522

27. Case J.B., Bailey A.L., Kim A.S., Chen R.E., Diamond M.S. Growth, detection, quantification, and inactivation of SARS-CoV-2. Virology 2020; 548: 39–48. https://pubmed.ncbi.nlm.nih.gov/32838945

28. Jureka A.S., Silvas J.A., Basler C.F. Propagation, Inactivation, and Safety Testing of SARS-CoV-2. Viruses 2020; 12(6): 622 doi: 10.3390/v12060622

29. Bojkova D., Widera M., Ciesek S., Wass M.N., Michaelis M., Cinatl J. Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates. Cell Res. 2022. https://doi.org/10.1038/s41422-022-00619-9

30. Tomita Y., Takeda M., Matsuyama S. The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells. Antimicrobial agents and chemotherapy. 2021; 65: e00020-21 doi: 10.1128/AAC.00020-21

31. Takashita E., Kinoshita N., Yamayoshi S., Sakai-Tagawa Y., Fujisaki S., Ito M. et al. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. New Engl. J. Med. 2022. 386(10): 995–8. doi: 10.1056/NEJMc2119407

32. Vangeel L., Chiu W., De Jonghe S., Maes P., Slechten B., Raymenants J. et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022; 198: 105252. doi: 10.1016/j.antiviral.2022.105252

33. Wang Y., Zhong W., Salam A., Tarning J., Zhan Q., Huang J.-A. et al. Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. EBioMedicine 2020; 62: 103125. http://europepmc.org/abstract/ MED/33232871

34. Irie K., Nakagawa A., Fujita H., Tamura R., Eto M., Ikesue H. et al. Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19. Clin. Trans. Sci. 2020; 13(5): 880–5. doi: 10.1111/cts.12827

35. Du Y.-X., Chen X.-P. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clin. Pharmacol. Ther. 2020; 108(2): 242–7. doi: 10.1002/cpt.1844

36. Arshad U., Pertinez H., Box H., Tatham L., Rajoli R.K.R., Curley P. et al. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Clin. Pharmacol. Ther. 2020; 108(4): 775–90. doi: 10.1002/cpt.1909

37. Pertinez H., Rajoli K.R., Khoo S.H., Owen A. Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5’-triphosphate exposure to support posology for SARS-CoV-2. J. Antimicrob. Chemother. 2021; 76 (Suppl 1). DOI:10.1093/jac/dkab135